Abstract
Background:After chemotherapy for nonseminomatous testicular germ cell tumor (NSTGCT), residual masses or recurrent disease may contain a non–germ cell malignancy (NGCM).
Methods:Over 20 years, 369 patients with disseminated NSTGCT were treated with cisplatin-based polychemotherapy at the University Medical Center Groningen. Residual tumor masses were resected in 244 patients and recurrent tumor masses in 37 patients. Histology was reviewed, focusing on the presence of NGCM.
Results:Nine patients developed an NGCM. Four patients had an NGCM in the resected residual tumor mass after chemotherapy: three patients had a sarcoma, and one patient had both a sarcoma and an adenocarcinoma. Five patients developed a late recurrence with an NGCM after 39, 40, 72, 72, and 84 months. One patient had a primitive neuroectodermal tumor, one had a sarcoma, and three had an adenocarcinoma in the resected recurrent tumor mass. A complete surgical resection was achieved in five (56%) of the nine patients. After a median follow-up of 48 months (range, 3–271 months), five patients had no evidence of disease (56%), three patients were dead of disease (33%), and one patient was alive with disease (11%).
Conclusions:Sarcoma, adenocarcinoma, or both in residual or recurrent tumor masses after combined-modality NSTGCT treatment are rare. Complete surgical resection of the tumor mass is the only curative treatment option.
Similar content being viewed by others
REFERENCES
Bosl GJ, Motzer RJ. Testicular germ-cell cancer. N Engl J Med 1997; 337: 242–53.
Horwich A, Huddart R, Dearnaley D. Markers and management of germ-cell tumours of the testes. Lancet 1998; 352: 1535–8.
Sonneveld DJ, Hoekstra HJ, Der Graaf WT, et al. Improved long term survival of patients with metastatic nonseminomatous testicular germ cell carcinoma in relation to prognostic classification systems during the cisplatin era. Cancer 2001; 91: 1304–15.
van Basten JP, Schraffordt Koops H, Sleijfer DT, Pras E, van Driel MF, Hoekstra HJ. Current concepts about testicular cancer. Eur J Surg Oncol 1997; 23: 354–60.
Little JS Jr, Foster RS, Ulbright TM, Donohue JP. Unusual neoplasms detected in testicular cancer patients undergoing postchemotherapy retroperitoneal lymphadenectomy. World J Urol 1994; 12: 200–6.
Sonneveld DJ, Sleijfer DT, Schraffordt Koops H, Keemers-Gels ME, Molenaar WM, Hoekstra HJ. Mature teratoma identified after postchemotherapy surgery in patients with disseminated nonseminomatous testicular germ cell tumors: a plea for an aggressive surgical approach. Cancer 1998; 82: 1343–51.
Toner GC, Panicek DM, Heelan RT, et al. Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol 1990; 8: 1683–94.
Comiter CV, Kibel AS, Richie JP, Nucci MR, Renshaw AA. Prognostic features of teratomas with malignant transformation: a clinicopathological study of 21 cases. J Urol 1998; 159: 859–63.
Michael H, Lucia J, Foster RS, Ulbright TM. The pathology of late recurrence of testicular germ cell tumors. Am J Surg Pathol 2000; 24: 257–73.
Motzer RJ, Amsterdam A, Prieto V, et al. Teratoma with malignant transformation: diverse malignant histologies arising in men with germ cell tumors. J Urol 1998; 159: 133–8.
Rebischung C, Cottu PH, Daban H, et al. Germ-cell tumours containing non germ-cell neoplasms: teratoma with malignant transformation. Urol Oncol 2001; 6: 239–42.
Ulbright TM, Loehrer PJ, Roth LM, Einhorn LH, Williams SD, Clark SA. The development of non-germ cell malignancies within germ cell tumors. A clinicopathologic study of 11 cases. Cancer 1984; 54: 1824–33.
Ahmed T, Bosl GJ, Hajdu SI. Teratoma with malignant transformation in germ cell tumors in men. Cancer 1985; 56: 860–3.
Cromheecke M, Mehta DM, Sleijfer DT, Molenaar WM, Schraffordt Koops H, Hoekstra HJ. The ultimate effect of intraoperative radiotherapy (IORT) on an irresectable retroperitoneal recurrence of a non-seminomatous testicular tumour. Radiother Oncol 1993; 29: 352–4.
Molenaar WM, Oosterhuis JW, Meiring A, Sleijfer DT, Schraffordt Koops H, Cornelisse CJ. Histology and DNA contents of a secondary malignancy arising in a mature residual lesion six years after chemotherapy for a disseminated nonseminomatous testicular tumor. Cancer 1986; 58: 264–8.
Oosterhuis JW, Suurmeyer AJ, Sleijfer DT, Schraffordt Koops H, Oldhoff J, Fleuren G. Effects of multiple-drug chemotherapy (cis-diammine-dichloroplatinum, bleomycin, and vinblastine) on the maturation of retroperitoneal lymph node metastases of nonseminomatous germ cell tumors of the testis. No evidence for de novo induction of differentiation. Cancer 1983; 51: 408–16.
Castedo SM, de Jong B, Oosterhuis JW, et al. Chromosomal changes in mature residual teratomas following polychemotherapy. Cancer Res 1989; 49: 672–6.
Bosl GJ, Donadio A, Kantoff P, Bajorin D, Motzer R, Sheinfeld J. Chemotherapy (Ctx) for teratoma with malignant transformation. Proc Am Soc Clin Oncol 2002; 21.
ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of mixed or non-seminomatous germ cell tumors (NSGCT). Ann Oncol 2001; 12: 1215–6.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Lutke Holzik, M.F., Hoekstra, H.J., Mulder, N.H. et al. Non–Germ Cell Malignancy in Residual or Recurrent Mass After Chemotherapy for Nonseminomatous Testicular Germ Cell Tumor. Ann Surg Oncol 10, 131–135 (2003). https://doi.org/10.1245/ASO.2003.05.024
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1245/ASO.2003.05.024